Anna Kaltenboeck

Employees With Fibromyalgia : Medical Comorbidity, Healthcare Costs, and Work Loss

Objectives: To compare 2005 health care resources among matched samples of employees with fibromyalgia (FM), osteoarthritis (OA), and controls. Methods: Using a claims database of privately insured individuals, FM and OA samples were derived from those with two or more disease-specific claims in 1999 to 2005 (≥1 in 2002 to 2005). Results: Total costs for employees with FM (

Comparison of Health Care Use and Costs in Newly Diagnosed and Established Patients With Fibromyalgia

10,199) approached OA costs (

Direct costs and survival of medicare beneficiaries with early and advanced parkinson’s disease

10,861, P = 0.3758) and were significantly higher than controls (

The Direct and Indirect Costs among U.S. Privately Insured Employees with Hypogonadism

5274, P < 0.0001). Cost components varied across disease-specific samples (direct medical: FM

Early retirement and income loss in patients with early and advanced Parkinson’s disease

7286 vs OA

An economic model of Parkinson's disease: implications for slowing progression in the United States.

8325, P < 0.0287; pharmacy: FM

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population

1630 vs OA

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.

1341; indirect: FM

Treatment patterns in patients with advanced gastric cancer in Taiwan

2913 vs OA

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

2537, P < 0.0001). Employees with FM had more claims than OA for psychiatric diagnoses, chronic fatigue, and most pain conditions. Use of multiple prescription drug classes was common in both samples. Conclusions: FM imposes significant economic burden. Work loss contributes substantially to the impact.